Medtronic Plc Hits New 52-Week Low at USD 77.44

Medtronic Plc, a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 77.44 as of May 5, 2026. This decline marks a significant point for the company, which has experienced a 1-year performance drop of 6.43%, contrasting sharply with the S&P 500's impressive gain of 28.47% during the same period. With a market capitalization of USD 113,290 million, Medtronic operates within a competitive landscape, characterized by a price-to-earnings (P/E) ratio of 20.00. The company maintains a dividend yield of 3.20%, reflecting its commitment to returning value to shareholders. Additionally, Medtronic's debt-to-equity ratio stands at a manageable 0.43, indicating a relatively low level of debt compared to equity. Despite the recent price decline, Medtronic has shown resilience in its operational metrics, with operating cash flow reaching a high of USD 7,146 million and a return on capital employed (ROCE) of 9.72%. The stock's performance has been bolstered by high institutional holdings at 86.93%, suggesting a robust backing from sophisticated investors.